©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Heterodimeric Neurotrophins Induce Phosphorylation of Trk Receptors and Promote Neuronal Differentiation in PC12 Cells (*)

(Received for publication, May 22, 1995; and in revised form, July 28, 1995)

James J. S. Treanor (1) (2)(§) Charles Schmelzer (2) Beat Knusel (3) John W. Winslow (1) David L. Shelton (1) Franz Hefti (1) Karoly Nikolics (1) Louis E. Burton (2)

From the  (1)Departments of Neuroscience and (2)Recovery Process Research and Development, Genentech, Incorporated, South San Francisco, California 94080-4990 and the (3)Andrus Gerontology Center, University of Southern California, Los Angeles, California 94080

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Neurotrophins are a family of highly conserved proteins that affect the development and maintenance of distinct neuronal populations. Neurotrophins exist in vivo as homodimers, but we show that neurotrophins can exist as heterodimers in vitro and are pluripotent, being able to bind and to activate different Trk tyrosine kinase receptors as well as promote neuronal differentiation in PC12 cells as effectively as wild type homodimers. These asymmetric neurotrophin dimers allow unique characterization of neurotrophin structure-function relationships with Trk receptors. The chimeric Trk activities of these heterodimers suggest an alternative model of neurotrophin-Trk receptor activation in which the critical Trk-interacting elements may be attributed to a single protomer.


INTRODUCTION

The neurotrophins represent a family of structurally conserved, basic proteins including nerve growth factor (NGF), (^1)brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), and neurotrophin-4/5 (NT4/5). These proteins are critical for the development and maintenance of a wide range of neuronal populations in both the peripheral and central nervous system (Purves, 1988; Thoenen, 1991). Neurotrophins are believed to exist in solution as non-covalent dimers (Angeletti et al., 1971; McDonald et al., 1991; Narhi et al., 1993) at physiologically relevant concentrations (Bothwell and Shooter, 1977). The protomers of the dimer are held together through non-polar interactions of a flat interface formed structurally by three anti-parallel pairs of beta-strands, which are highly conserved in terms of primary sequence, between all known neurotrophins (McDonald et al., 1991). The neurotrophins exert their biological effects through selective interaction with and proposed dimerization (Jing et al., 1992) of a family of high affinity tyrosine kinase receptors (Trks) such that NGF binds primarily to TrkA (Kaplan et al., 1991a, 1991b; Klein et al., 1991a), BDNF (Klein et al., 1991b; Soppet et al., 1991; Squinto et al., 1991), and NT4/5 (Berkemeier et al., 1991; Escandon et al., 1993) to TrkB and NT3 to TrkC (Lamballe et al., 1991; Tsoulfas et al., 1993). It has been argued that a single neurotrophin dimer interacts with two Trk receptors to form a functional receptor homodimer (Jing et al., 1992; Meakin and Shooter, 1992; Ibanez et al., 1993) and that the high affinity interaction between the receptor subunits and the neurotrophin is the driving force for receptor dimerization.

We have previously shown that chimeric neurotrophin dimers can be formed from human and mouse NGF and that these act identically to either human or mouse NGF homodimers in bioassays (Moore and Shooter, 1975; Burton et al., 1992; Luo and Neet, 1992; Schmelzer et al., 1992). We and others have also shown that three different COOH-terminal forms of recombinant human NGF are capable of forming chimeric dimers that exhibit biological activity (Moore and Shooter, 1975; Burton et al., 1992; Luo et al., 1992).

Analysis of residues with high surface accessibility, at the interface of the mouse NGF homodimer, indicates a strict conservation of this structure between the different members of the neurotrophin family. (^2)The high degree of homology between interface residues led us to hypothesize that it might be possible to form heterodimeric neurotrophins. Furthermore, since these molecules would contain the variable domains from two different neurotrophins with similar tertiary structure, we were interested to see how active these molecules would be in terms of receptor binding.

Evidence from proteolyzed neurotrophins and mutagenesis has shown that the amino terminus is the most important binding determinant for interaction of NGF with the TrkA receptor (Moore and Shooter, 1975; Burton et al., 1992; Ibanez et al., 1992; Kahle et al., 1992; Luo and Neet, 1992; Shih et al., 1994). Since neurotrophin heterodimers would have two distinct amino termini, it was also necessary to determine whether both amino termini were implicit in a functional interaction with the receptor. To this end, asymmetric neurotrophin heterodimers were generated to act as specific probes to investigate some of the structural elements important for neurotrophin-receptor interactions.


EXPERIMENTAL PROCEDURES

Heterodimer Production, Purification, and Stability

Neurotrophins used for the production of heterodimer neurotrophins were generated as described by Schmelzer et al.(1992) and Burton et al.(1992). Acid-driven rearrangement has been used to generate a series of potential neurotrophin heterodimers, which are at present being assayed. All proteins were analyzed for their amino acid compositions using a Beckman 6300 amino acid analyzer and quantitated relative to a norleucine internal standard before use. Neurotrophins were stored in 20 mM sodium/potassium phosphate buffer, 200 mM KCl, pH 7.2. For the stability studies, samples were stored at four temperatures (37, 25, 4, and -70 °C) for up to 300 h, and 10-µg aliquots were monitored during this time course by HPIEC. Percent composition was calculated using peak integration.

Radioligand Receptor Binding

This cell suspension binding assay is essentially that described by Vale and Shooter(1985). Briefly, 1 times 10^5 cells, resuspended in 200 µl of Leibovitz's L15 media without NaHCO(3) (Life Technologies, Inc.) (with 10 mM HEPES, pH 7.4, and 1 mg/ml bovine serum albumin), were vigorously agitated at room temperature for 1 h with the iodinated neurotrophin (30-50 pM, specific activity 250 cpm/pg) and competed with a range of concentrations of unlabeled neurotrophin; each point was carried out in triplicate. The iodinated ligand concentration could be decreased 10-fold with no apparent change in IC. Neurotrophins were iodinated using a modified enzymobead procedure (Bio-Rad) described by Escandon et al.(1993), and the concentration was estimated by trichloroacetic acid precipitation. Free and bound counts were separated by centrifugation through a phosphate-buffered saline 0.15 M sucrose cushion. Examples of displacement binding curves are presented as the percentage of total I-neurotrophin bound such that both specific displaceable counts and nonspecific binding can easily be seen. Each point was determined in triplicate, and the mean IC values shown in Table 1are averaged from over four separate determinations.



Receptor Phosphorylation Assays

Neurotrophin heterodimers were assayed for their ability to induce phosphorylation using a cell suspension assay. Cells were harvested and resuspended in Leibovitz's L15 media without NaHCO(3) (Life Technologies, Inc.) (with 10 mM HEPES, pH 7.4, and 1 mg/ml bovine serum albumin) and stored on ice before use. 1 times 10^6 TrkA- or TrkB receptor-expressing cells (a gift from Dr. L. Parada) or 5 times 10^6 PC12 cells were stimulated with a range of concentrations of neurotrophin for 10 min at 37 °C in a total volume of 200 µl. Cells were immediately centrifuged, washed, and placed in 500 µl of ice-cold lysis buffer (50 mM HEPES, pH 7.4, 100 mM NaF, 4 mM EDTA, 10 mM sodium pyrophosphate, 2 mM sodium vanadate, 1% Nonidet P40, 0.1 mM phenylmethylsulfonyl fluoride, 0.1 mMN-ethylamaleimide, 8.5 mg/ml aprotinin) on ice. Proteins that were tyrosine phosphorylated were immunoprecipitated with agarose-linked anti-phosphotyrosine antibodies (Oncogene Science) and solubilized, and Western blots of these samples were probed with a pan-anti-Trk antibody (a gift from Dave Kaplan).

NGF:NT4/5 was also compared to NT4/5 for its ability to stimulate phosphorylation of Trk receptors in primary cultures of fetal rat cortex (Wistar, embryonic age E15-E16; Charles River, Wilmington, MA). Primary cultures were prepared as previously described (Knusel et al., 1990). Cultures grown for 6 days were treated with neurotrophin for 4 min and immediately lysed in 0.5 ml of lysis buffer (137 mM NaCl, 20 mM Tris, pH 8.0, 1% Triton X-100, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM sodium orthovanadate) at 4 °C. The samples were centrifuged for 10 min at 10,000 times g, and the supernatant was stored frozen at -70 °C. Trk receptors were then immunoprecipitated with a pan-Trk receptor anti-serum (a gift from Dr. David Kaplan). Samples were Western blotted and probed with an anti-phosphotyrosine antibody as described in detail elsewhere (Kaplan et al., 1991a, 1991b). Choline acetyltransferase activity was determined as previously described (Knusel et al., 1994).

PC12 Neurite Outgrowth Assays

PC12 cells were tested using an accelerated response paradigm (Greene et al., 1987) to decrease the possibility of neurotrophin rearrangement affecting the neurite outgrowth response. PC12 cells were first ``primed'' by growth in the presence of 50 ng/ml NGF for 10 days. The cells were washed and replated at low seeding density in the presence of a range of concentrations of neurotrophin and left for 24 h before neurite-bearing cells were counted. Shorter periods of stimulation were tested using a wash-out protocol in which neurotrophins were left on the cells for 1.5, 3, or 6 h or for the full assay period of 24 h. Each point was analyzed in quadruplicate and in separate wells. Approximately 150-200 cells were counted per well.


RESULTS

Production of Heterodimer Neurotrophins

Two neurotrophin heterodimers, that of full-length NGF and NT4/5 (NGF:NT4/5) as well as a NGF dimer of full-length NGF and an amino-terminal truncated des-1-9 NGF (NGF:Delta9NGF), are now reported. Heterodimeric neurotrophins were prepared by the acidification and subsequent neutralization of combined pools of homogeneous, intact, or proteolytically altered recombinant human neurotrophins, as has been used previously for the purification of chimeric NGF dimers (Moore and Shooter, 1975; Burton et al., 1992; Luo and Neet, 1992; Schmelzer et al., 1992). This procedure resulted in a mixture of species including homo- and heterodimeric neurotrophin molecules, which were purified to homogeneity by HPIEC (Moore and Shooter, 1975; Burton et al., 1992; Luo et al., 1992; Schmelzer et al., 1992) (Fig. 1A). SDS-polyacrylamide gel electrophoresis and reversed phase high performance liquid chromatography (HPLC) showed that the purified heterodimer could be separated into two equimolar bands (Fig. 1B) or peaks (Fig. 1C), which corresponded to both component neurotrophin proteins. Reversed phase HPLC peaks, when recombined and neutralized, formed the same ratio of peak fraction sizes and retention times seen during the initial purification by HPIEC (data not shown). This technique has now been used successfully to generate a large number of different neurotrophin heterodimers. Radziejewski and Robinson(1993) have shown that heterodimer formation can be accelerated using not only acidic conditions but also with solvents and urea. Stability studies were carried out on samples stored under physiological salt and pH conditions at four temperatures. Aliquots removed at selected times were analyzed by HPIEC, and the rates of breakdown of NGF:Delta9NGF and NGF:NT4/5 were estimated (Fig. 1D). The stability of the heterodimers was temperature dependent. The rate of breakdown was very slow at -70, 4, and 25 °C but faster at 37 °C. By this criteria, we were able to exclude the possibility that homodimer neurotrophins were reformed from dissociated heterodimer in quantities able to significantly affect the assays carried out subsequently. To further control for any possible variations, matched series of dilutions were used for both the receptor binding and phosphorylation experiments.


Figure 1: A shows the separation of neurotrophins by HPIEC at A. Panel1, NT4/5; panel2, NGF:NT4/5; panel3, NGF; panel4, pre-HPIEC pool of heterodimer preparation. B, SDS-polyacrylamide gel electrophoresis was performed using 5 µg of each protein on 15% polyacrylamide slab gels with a 4% stacking gel (both contained 3.8 M urea). Gels were silver stained (Morrissey, 1981). Lane1, NT4/5; lane2, NGF:NT4/5; lane3, NGF; lane4, low molecular weight standards (Pharmacia). C shows the analytical reverse phase separation of neurotrophins using a Vydac C(4) reversed phase HPLC. Panel1, NGF; panel2, NT4/5; panel3, NGF:NT4/5. D shows the thermal-dependent rates of decay of NGF:NT4/5 and NGF:Delta9NGF at 37, 25, 4, and -70 °C.



HPIEC peak ratios during initial production of heterodimers match the equilibrium peak ratios observed during rearrangement of heterodimers at 37 °C in the stability studies carried out. These peak ratios and the rate at which they rearrange most likely reflect the relative affinities of the different neurotrophin protomers for each other. It is difficult to compare rearrangement rates in homodimers due to difficulties in tagging the individual protomer subunits of the dimer accurately. Stability studies were carried out on human NGF(120):NGF(118) and show very similar rates of breakdown to NGF:Delta9NGF (data not shown). NGF(118) homodimer has the two most proximal COOH-terminal residues removed (Arg-119, Ala-120) but displays full bioactivity and binding when compared to full-length NGF (Burton et al., 1992; Schmelzer et al., 1992). This suggests that while individual neurotrophin protomers have a very high affinity for each other (Bothwell and Shooter, 1977), they undergo rearrangement even in their intact homodimeric state. This is important since it suggests that heterodimers could be formed in any situation where two or more neurotrophin homodimers exist together. Furthermore, Jungbluth et al.(1994) showed that co-expression of neurotrophins (NT-3 and BDNF) in a single cell line can result in the formation of a mixture of homo- and heterodimers in the culture medium.

Radioligand Receptor Binding of Heterodimers

Radioligand-receptor binding assays were carried out on a number of different cell lines expressing specific neurotrophin receptors. IC values obtained by competition binding isotherms were averaged and are summarized in Table 1. Both NGF:Delta9NGF and NGF:NT4/5 were as effective as either homodimeric NGF or NT4/5 at displacing I-NGF from the low affinity p75 receptor of A875 cells (for example, see Fig. 2A), suggesting that the hybrid molecules had a structural conformation comparable to homodimeric neurotrophins at least with regard to the p75 binding region(s). A putative p75 binding site is structurally close to residues involved in Trk receptor binding (Ibanez et al., 1992) such that p75 receptor interactions act as a reasonable control for the overall conformational structure of the heterodimeric proteins.


Figure 2: Examples of competition binding isotherms of NGF:NT4/5 and NGF:Delta9NGF to A875, PC12, and TrkA- or TrkB expressing NIH 3T3 cells. A, B, C, and E represent A875 (p75 only), PC12 (p75 and TrkA), and TrkA (only) expressing cell binding of I-NGF and competition with unlabeled NGF, NGF:NT4/5, NT4/5, NGF:Delta9NGF, and homodimeric Delta9 NGF. D represents TrkB-expressing cell binding of I-labeled NT4/5 and competition with unlabeled NGF, NGF:NT4/5, and NT4/5.



In PC12 cells, a rat pheochromocytoma cell line, which expresses p75 and a smaller number of TrkA receptors, NGF:Delta9NGF and NGF:NT4/5, were able to displace all specifically bound I-NGF, as efficiently as NGF, while homodimeric NT4/5 displaced a maximum of 80% (probably corresponding to the p75 component) (for example, see Fig. 2B). These results suggested that both NGF:Delta9NGF and NGF:NT4/5 were able to displace not only the p75 component of PC12 cell binding but also the TrkA specific component. Radioligand-receptor binding was then studied on NIH 3T3 cells selectively expressing rat TrkA (Kaplan et al., 1991a, 1991b) or rat TrkB (Soppet et al., 1991) using matched dilution curves of the homo- and heterodimeric neurotrophins. Both NGF:NT4/5 (for example, see Fig. 2C) and NGF:Delta9NGF (for example, see Fig. 2E) were able to displace I-NGF from TrkA-expressing NIH 3T3 cells showing an average 2-fold increase in IC compared to homodimeric NGF (Table 1), whereas NT4/5 was only able to displace I-NGF from the TrkA receptor if taken to micromolar concentrations (for example, see Fig. 2C). NGF:NT4/5 displayed a 20-fold increase in IC compared to NT4/5 for displacement of I-labeled NT4/5 from the rat TrkB receptor, while no displacement was detectable with NGF (for example, see Fig. 2D). These results indicate that binding interactions of NGF:Delta9NGF and NGF:NT4/5 with the rat TrkA receptor are very similar to homodimeric NGF. Although NGF:NT4/5 binds rat TrkB 20-fold less efficiently than NT4/5, the binding is clearly significant compared to homodimeric NGF with the TrkB receptor. Importantly, preliminary results analyzing the displacement binding properties of NGF:NT4/5 from cells expressing the human TrkA or human TrkB receptors indicate only 2-3-fold increases in IC when compared to cognate homodimeric neurotrophins. These observations suggest that the differences seen with NGF:NT4/5 on the rat TrkB-expressing cell line could be due to species variations in the receptor (data not shown). Small variations seen in IC values may be due to slight variations in conformation of the receptor binding domain of the heterodimer or perhaps differential involvement of amino termini in binding to their cognate Trk receptor.

To further investigate the promiscuity of the amino termini between neurotrophins with regard to their potential involvement with binding domains on the other protomer of the dimer, a small quantity of heterodimeric Delta9NGF:NT4/5 was generated, and some preliminary binding studies were carried out. Delta9NGF:NT4/5 displaces I-labeled NT4/5 bound to human TrkB similar to homodimeric NT4/5 and I-NGF from human TrkA similar to Delta9NGF (300-fold less than homodimeric NGF). The loss of an amino terminus from NGF does not appear to alter the interaction of NT4/5 with TrkB, and the presence of an amino terminus of NT4/5 in the dimeric structure of Delta9NGF:NT4/5 does not facilitate Delta9NGF binding to the TrkA receptor, consistent with the data generated with NGF:NT4/5.

Signal Transduction by Heterodimeric Neurotrophins

Several tyrosine residues found within the conserved tyrosine kinase domain of the Trk family of receptors are phosphorylated in a dose-dependent manner upon exposure to their cognate neurotrophin. This signal transduction event is rapid with peak phosphorylation seen within 5 min, such that the breakdown of NGF:Delta9NGF or NGF:NT4/5 would be less than 0.1% during the time course of this assay. NGF:NT4/5 and NGF:Delta9NGF were able to induce phosphorylation of the TrkA receptor as efficiently as NGF (Fig. 3, A and B), while homodimeric NT4/5 and fully truncated NGF induced significantly lower phosphorylation. The increased IC of NGF:NT4/5 in competition binding studies on the rat TrkB receptor was paralleled by an approximately 20-fold decrease in the phosphorylation of the TrkB receptor when compared to NT4/5 (Fig. 3A), while homodimeric NGF induced no detectable phosphorylation. Similar to the results with NGF:NT4/5 stimulation of TrkB in fibroblasts, primary cultures of rat cortex showed an approximate 10-fold decrease in phosphorylation of Trk receptors compared to NT4/5 (Fig. 3C). These results indicate that both NGF:Delta9NGF and NGF:NT4/5 are capable of binding and initiating a signal transduction event through phosphorylation of Trk receptors.


Figure 3: Characterization of biological activity of heterodimeric neurotrophins. A and B are Western blots that show the dose dependence of Trk receptor phosphorylation to four concentrations of neurotrophins. A shows the response to 1) NGF, 2) NGF:NT4/5, and 3) NT4/5 of TrkA- and TrkB-expressing 3T3 cells and ``primed'' PC-12 cells, respectively. B shows the response to 1) NGF, 2) NGF:Delta9NGF, and 3) Delta9NGF of TrkA-expressing 3T3 cells. C shows the dose-dependent phosphorylation of Trk receptors in rat cortical cultures after stimulation with either NGF:NT4/5 or NT4/5. D shows the time-dependent response of primed PC12 cells to NGF exposure using a wash-out paradigm and counting at 24 h after initial stimulation. E shows the dose-dependent response in neurite outgrowth of primed PC12 cells to NGF, NGF:NT4/5, NGF:Delta9NGF, or Delta9 NGF but not to NT4/5.



Biological Analysis of Heterodimer Activities

Neurotrophins were tested in a ``primed'' PC12 cell bioassay (Greene et al., 1987) (Fig. 3, D and E). These cells respond to NGF, changing from a chromaffin cell to a neuronal-like phenotype, with increased size and neuritic projections. In an accelerated paradigm, these cells respond to NGF within 24 h (Greene et al., 1987). Analysis of neurite outgrowth in PC12 cells stimulated for varying time periods (1.5, 3, 6, and 24 h with wash out) showed almost equivalent dose-dependent response in the percentage of cells bearing neurites (Fig. 3D), although qualitatively it appeared that the cells stimulated for longer periods were more robust in terms of cell size. This suggests that the mechanism that controls neurite outgrowth in ``primed'' PC12 cells is induced relatively quickly and that perhaps the steady-state level of neurotrophin/receptor binding reached in the first few hours of the assay is critical to the response seen after 24 h. Both NGF:NT4/5 and NGF:Delta9NGF were able to induce neurite outgrowth as efficiently and with similar potency as NGF on PC12 cells (Fig. 3E), whereas Delta9NGF and NT4/5 showed a greatly decreased or non-detectable EC, respectively. Together with the stability data (Fig. 1D), these results suggest that the bioactivity observed is due to the heterodimer and not as a consequence of reassociated NGF. It appears, from these experiments that the ability of a neurotrophin to displace ligand from the Trk receptor correlates positively with the ability of these molecules to induce both signal transduction and biological response. In addition, these results suggest that only one intact NGF amino terminus attached to the NGF dimer structure is sufficient for the functional activity of the neurotrophin, consistent with the results seen with NGF:NT4/5.

Proteolytic cleavage of the amino termini from other neurotrophin family members leads to equivalent increases in IC of neurotrophin displacement from the cognate Trk receptor, as seen with NGF and Delta9NGF interactions with the TrkA receptor, suggesting a general requirement for this structural feature (data not shown). At present, it is unclear whether both amino termini of the neurotrophins act solely as a site of Trk interaction or whether they might also contribute to the stability of neurotrophin dimeric structure. Amino-terminal-deleted neurotrophins remain competent in terms of p75 binding, which probably indicates little effect on overall structure.


DISCUSSION

In this report, we demonstrate the capability of neurotrophin family members to form heterodimers that appear to be relatively stable. These molecules are asymmetric neurotrophin dimers, in contrast to symmetric dimers of neurotrophin produced by mutagenesis, and as such can be used as unique structural probes for ligand-receptor binding interactions and activation. Surprisingly, their demonstrated specificity for receptor interactions and biological activity appears to be largely predictable from the homodimer equivalents of their subunit parts. Furthermore, analysis of the amino terminus of NGF suggests that only one intact amino terminus is necessary for NGF to elicit significant actions through the TrkA receptor. These findings suggest that the binding surface(s) sufficient for NGF receptor-ligand interactions can be largely carried on each protomer of the dimeric molecule.

A structural model of NGF-Trk receptor interactions has been proposed based upon extensive mutagenesis of variable sequence regions identified within the neurotrophin family (Ibanez et al., 1991, 1992, 1993; Suter et al., 1992; Shih et al., 1994). In our present work and in previous studies (Moore and Shooter, 1975; Burton et al., 1992; Kahle et al., 1992; Luo and Neet, 1992; Shih et al., 1994), we have observed that the amino-terminal region of NGF is critical for high affinity binding and biological activity. In agreement with this, Ibanez et al.(1993) suggest that the amino terminus may be the most significant contributor to the binding energy of NGF with TrkA. Other sites of receptor interaction, i.e. between variable regions I, II, IV, and V, although helping to stabilize the ligand-receptor complex, appear to be secondary. In contrast to the proposed nature of the amino terminus-receptor interaction, the other variable regions, particularly region II, may be involved in receptor activation more than receptor binding (Ibanez et al., 1993). The proposed models of NGF-Trk interaction suggest that multiple specific contacts within the variable regions of NGF, described above, form a continuous binding surface on both sides of the molecule (Ibanez et al., 1993). The bivalent nature of this proposed binding surface is consistent with the 2-fold symmetry of NGF suggested to be responsible for Trk dimerization and signal transduction (Fig. 4B, model1) (Jing et al., 1992). Structural elements from both protomers have been implied to contribute to the binding surface. For example, part of the Trk binding/activation surface of NGF has been suggested to be a patch of residues that contains variable regions I, IV, and V from one protomer and region II and possibly the amino terminus from the other protomer. NGF:Delta9NGF has similar biological activity to homodimeric NGF, suggesting that this proposed domain on NGF involving the amino termini and variable regions does not have to be bilateral for receptor binding, signal transduction, and thus receptor dimerization to occur. It is important to note that these variable regions and the amino-terminal sequences are very different between NGF and NT4/5, yet NGF:NT4/5 has been shown to be nearly equipotent to homodimeric NGF in its interactions with and through TrkA. This is consistent with the suggestion that the amino terminus from one protomer is not involved in a binding domain on the other protomer. The significant variability in the primary sequence of the amino termini and regions I-V between neurotrophins brings into question the cooperation of variable domains across protomers in the formation of an extended binding/activation domain in NGF:NT4/5 and by analogy, therefore, in the NGF dimer structure. Matched dilution curves of NGF:NT4/5 displayed significant TrkB receptor binding and autophosphorylation activity compared to NGF but a 10-20-fold loss in comparison to NT4/5. This could reflect differences either in the binding domains of NT4/5 and TrkB compared to NGF and TrkA or simply a species-related difference between rat and human TrkB receptors. Competition binding indicates that I-labeled NT4/5 displacement is only shifted 2-3-fold with NGF:NT4/5 compared to NT4/5 when analyzed on cells expressing the human TrkB receptor (data not shown). Another heterodimer, that of Delta9NGF:NT4/5, was able to displace I-labeled NT4/5 from the human TrkB receptor similar to homodimeric NT4/5 but unable to displace NGF from the human TrkA receptor effectively. This is consistent with the data from NGF:NT4/5 and further indicates that the amino termini are not promiscuous in their interactions between protomers to form binding domains. The amino termini do appear to be a very mobile domain in solution as the lack of electron density indicates in the murine NGF crystallographic structure (McDonald et al., 1991; Holland et al., 1994). However, the exact role(s) of the amino termini in NGF dimer stability and in binding domains remains unclear.


Figure 4: Representation of the tertiary structure of murine NGF and models of possible neurotrophin-receptor interactions. A, this sketch represents a single protomer of the NGF dimer (McDonald et al., 1991). The dimer is formed by non-polar interactions of residues situated on three anti-parallel pairs of beta-strands (B-D). These residues are highly conserved between all known neurotrophins, and any substitutions tend to be the same in terms either of size or of nature. The four variable domains are marked I-IV. The amino and carboxyl termini are marked as well as the regional nomenclature described by Ibanez et al.(1993). B, the present results suggest the possibility of alternative models of ligand-induced receptor dimerization of the neurotrophin family with the high affinity Trk receptor family. Models1 and 2 indicate a cross-bridging dimerization of the Trk receptors, whereas models3 and 4 indicate an interaction with a single receptor leading to dimerization with and trans-phosphorylation of the other receptor.



The current data suggest an alternative mechanism for NGF-Trk receptor signal transduction in which the NGF binding/activation domains are contained primarily upon a single protomer (Fig. 4B, model2). Co-crystallization of the soluble human growth hormone receptor-ligand complex reveals that a single protomeric hormone can dimerize two identical receptors through interactions with two distinct binding domains (Cunningham et al., 1991). Our preliminary results with other heterodimeric neurotrophin combinations indicate that they display dual activities consistent with their subunit parts and this model. The potential involvement of conserved residues upon binding interactions with Trk receptors is under further study. It will be interesting to produce heterodimers containing mutated protomers to analyze whether dimerization of Trk receptors is induced by cross-bridging with the neurotrophin (Fig. 4B, model1 and 2) or perhaps by other receptor interactions which in turn induce receptor dimerization and trans-phosphorylation (Fig. 4B, models3 and 4).

In addition to providing an approach to investigating Trk receptor signal transduction, the relative stability and biological activity of heterodimeric neurotrophins suggests that they could represent novel pharmacological agents in vivo. For example, in models of peripheral neuropathy, certain neuronal populations, such as dorsal rat ganglia sensory neurons (McMahon et al., 1994), express multiple Trk receptors and may be responsive to pluripotent heterodimeric neurotrophins. Interestingly, multiple neurotrophins can be co-expressed in some neurons (Philips et al., 1990) and glioma cell lines (Hamel et al., 1993). Jungbluth et al.(1994), using the co-expression of NT-3 and BDNF in a rabbit kidney cell line (RK13) by vaccinia virus, have shown that heterodimers can be purified from serum-free conditioned medium and show some biological activity. Our stability data, generated in vitro under physiological conditions, indicate that heterodimers rearrange to an equilibrium containing significant amounts of heterodimer (40-50%), which suggests the possibility that neurotrophin heterodimers may exist in vivo. Whether or not neurotrophin heterodimers exist in a neuronal context remains an intriguing question.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by National Institutes of Health Grant AG10480-04 and Genentech Inc. To whom correspondence should be addressed: Dept. of Neuroscience, Genentech, Inc., 460 Point San Bruno Blvd., South San Francisco, CA 94080-4990. Tel.: 415-225-2514; Fax: 415-225-6240.

(^1)
The abbreviations used are: NGF, nerve growth factor; BDNF, brain-derived growth factor; NT-3, neurotrophin-3; NT4/5; neurotrophin 4/5; NGF(120), mature full length human NGF residues 1-120; NGF(118), NGF with a 2-amino acid residue deletion from carboxyl terminus; Delta9-NGF; homodimer of NGF with proximal 9 NH(2)-terminal amino acid residues deleted; NGF:Delta9-NGF, heterodimer of NGF containing a single protomer of NGF and a protomer of Delta9-NGF; NGF:NT4/5, heterodimer of a single protomer of NGF and a single protomer of NT4/5; p75, p75 low affinity NGF receptor; TrkA, p140 tyrosine kinase NGF receptor, HPIEC, high performance ion exchange chromatography; HPLC, high performance liquid chromatography; IC, concentration of competing ligand that results in 50% inhibition of specific binding of I-neurotrophin to its cognate receptor; pan, pantothenate.

(^2)
J. J. S. Treanor and W. Somers, unpublished observations.


ACKNOWLEDGEMENTS

We are grateful to Dr. L. Parada for the gift of the Trk- and TrkB-expressing NIH 3T3 cell lines and Dr. D. Kaplan for the use of the pan-Trk antibody. We thank Evelyn Martin for the early contributions in the pilot production of neurotrophin heterodimers. We thank Dr. T. Brennan and Deanna Grant for discussion and support. We thank J. Murray-Rust for the coordinates of murine NGF and Dr. W. Somers and the Dept. of Protein Engineering for help with protein modeling. The NGF structure was drawn using the ``Molscript'' program designed by J. Kraulis.


REFERENCES

  1. Angeletti, R. H., Bradshaw, R. A. & Wade, R. D. (1971) Biochemistry 10,463-469 [Medline] [Order article via Infotrieve]
  2. Berkemeier, L. R., Winslow, J. W., Kaplan, D. R., Nikolics, K., Goeddel, D. & Rosenthal, A. (1991) Neuron 7,857-866 [Medline] [Order article via Infotrieve]
  3. Bothwell, M. A. & Shooter, E. M. (1977) J. Biol. Chem. 252,8532-8536 [Abstract]
  4. Burton, L. E., Schmelzer, C. H., Szonyi, E., Yedinak, C. & Gorrell, A. J. (1992) Neurochemistry 59,1937-1945
  5. Cunningham, B. C., Ultsch, M., De Vos, A. M., Mulkerrin, M. G., Clauser, K. R. & Wells, J. A. (1991) Science 254,821-825 [Medline] [Order article via Infotrieve]
  6. Escandon, E., Burton, L. E., Szonyi, E. & Nikolics, K. (1993) J. Neurosci. Res. 34,601-613 [Medline] [Order article via Infotrieve]
  7. Greene, L. A., Aletta, J. M., Rukenstein, A. & Green, S. H. (1987) Methods Enzymol. 147,207-216 [Medline] [Order article via Infotrieve]
  8. Hamel, W., Westphal, M., Szonyi, E., Escandon, E. & Nikolics, K. (1993) J. Neurosci. Res. 34,147-157 [Medline] [Order article via Infotrieve]
  9. Holland, D. R., Cousens, L. S., Meng, W. & Matthews, B. W. (1994) J. Mol. Biol. 239,385-400 [CrossRef][Medline] [Order article via Infotrieve]
  10. Ibanez, C. F., Ebendal, T. & Persson, H. (1991) EMBO J. 10,2105-2110 [Abstract]
  11. Ibanez, C. F., Ebendal, T., Barbany, G., Murray-Rust, J., Blundell, T. L. & Persson, H. (1992) Cell 69,329-341 [Medline] [Order article via Infotrieve]
  12. Ibanez, C. F., Ilag, L. L., Murray-Rust, J. & Persson, H. (1993) EMBO J. 12,2281-2293 [Abstract]
  13. Jing, S., Tapley, P. & Barbacid, M. (1992) Neuron 9,1067-1079 [Medline] [Order article via Infotrieve]
  14. Jungbluth, S., Bailey, K. & Barde Y-A. (1994) Eur. J. Biochem. 221,677-685 [Abstract]
  15. Kahle, P., Burton, L. E., Schmelzer, C. H. & Hertel, C. (1992) J. Biol. Chem. 267,22707-22710 [Abstract/Free Full Text]
  16. Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V. & Parada, L. F. (1991a) Science 252,554-558 [Medline] [Order article via Infotrieve]
  17. Kaplan, D. R., Martin-Zanca, D. & Parada, L. F. (1991b) Nature 350,158-160 [CrossRef][Medline] [Order article via Infotrieve]
  18. Klein, R., Jing, S., Nanduri, V., O'Rourke, E. & Barbacid, M. (1991a) Cell 65,189-197 [Medline] [Order article via Infotrieve]
  19. Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F. & Barbacid, M. (1991b) Cell 66,395-403 [Medline] [Order article via Infotrieve]
  20. Knusel, B., Michel, P. P., Schwaber, J. S. & Hefti. F. (1990) J. Neurosci. 10,558-570 [Abstract]
  21. Knusel, B., Rabin, S. J., Hefti, F. & Kaplan, D. R. (1994) J. Neurosci. 14,1542-1554 [Abstract]
  22. Lamballe, F., Klein, R. & Barbacid, M. (1991) Cell 66,967-979 [Medline] [Order article via Infotrieve]
  23. Luo, Y. & Neet, K. E. (1992) J. Biol. Chem. 267,12275-12283 [Abstract/Free Full Text]
  24. McDonald, N. Q., Lappato, R., Murray-Rust, J., Gunning, J., Wlodower, A. & Blundell, T. L. (1991) Nature 354,411-414 [CrossRef][Medline] [Order article via Infotrieve]
  25. McMahon, S. B., Armanini, M. P., Ling, L. H. & Phillips, H. S. (1994) Neuron 12,1161-1171 [Medline] [Order article via Infotrieve]
  26. Meakin, S. O. & Shooter, E. M. (1992) Trends Neurosci. 15,323-331 [CrossRef][Medline] [Order article via Infotrieve]
  27. Moore, J. B. & Shooter, E. M. (1975) Neurobiology 5,369-381 [Medline] [Order article via Infotrieve]
  28. Morrissey, J. H. (1981) Anal. Biochem. 117,307-310 [Medline] [Order article via Infotrieve]
  29. Narhi, L. O., Rosenfeld, R., Talvenheimo, J., Prestrelski, S. J., Arakawa, T., Lary, J. W., Kolvenback, C. G., Hecht, R., Boone, T., Miller, J. A. & Yphantis, D. A. (1993) J. Biol. Chem. 268,13309-13317 [Abstract/Free Full Text]
  30. Phillips, H. S., Hains, J. S., Laramee, G. R., Rosenthal, A. & Winslow, J. W. (1990) Science 250,290-294 [Medline] [Order article via Infotrieve]
  31. Purves, D. (1988) Body and Brain: A Trophic Theory of Neural Connections , Harvard University Press, Cambridge, MA
  32. Radziejewski, C. & Robinson, R. C. (1993) Biochemistry. 32,13350-13356 [Medline] [Order article via Infotrieve]
  33. Schmelzer, C. H., Burton, L. E., Chan, W-P., Martin, E., Gorman, C., Canova-Davis, E., Ling, V. T., Sliwkowski, M. B., McCray, G., Briggs, J., Nguyen, T. H. & Polastri, G. (1992) J. Neurochem. 59,1675-1683 [Medline] [Order article via Infotrieve]
  34. Shih, A., Laramee, G. R., Schmelzer, C. H., Burton, L. E. & Winslow, J. W. (1994) J. Biol. Chem. 269,27679-27686 [Abstract/Free Full Text]
  35. Soppet, D., Escandon, E., Maragos, J., Middlemas, D. S., Reid, S. W., Blair, J., Burton, L. E., Stanton, B., Kaplan, D. R., Hunter, T., Nikolics, K. & Parada, L. F. (1991) Cell 65,895-903 [Medline] [Order article via Infotrieve]
  36. Squinto, S. P., Stitt, T. N., Aldrich, T. H., Davis, S., Bianco, S. M., Radziejewski, C., Glass, D. J., Masiakowski, P., Furth, M. E., Valenzuela, D. M. & Yancopoulos, G. D. (1991) Cell 65,885-893 [Medline] [Order article via Infotrieve]
  37. Suter, U., Angst, C., Tien, C. L., Drinkwater, C. C., Lindsay, R. M. & Shooter, E. M. (1992) J. Neurosci. 12,306-318 [Abstract]
  38. Thoenen, H. (1991) Trends Neurosci. 14,165-170 [CrossRef][Medline] [Order article via Infotrieve]
  39. Tsoulfas, P., Soppet, D., Escandon, E., Tessarollo, L., Mendoza-Ramirez, J.-L., Rosenthal, A., Nikolics, K. & Parada, L. F. (1993) Neuron 10,975-990 [Medline] [Order article via Infotrieve]
  40. Vale, R. D. & Shooter, E. M. (1985) Methods Enzymol. 109,21-39 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.